Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Debt / NOTE 1.000% 8/1
-
Market price (% of par)
-
140.75%
-
Total 13F principal
-
$655,325,460
-
Principal change
-
+$47,260,160
-
Total reported market value
-
$920,432,391
-
Number of holders
-
63
-
Value change
-
+$102,237,538
-
Number of buys
-
24
-
Number of sells
-
45
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q3 2025
As of 30 Sep 2025,
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 was held by
63 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$655,325,460
in principal (par value) of the bond.
The largest 10 bondholders included
MILLENNIUM MANAGEMENT LLC, LMR Partners LLP, Calamos Advisors LLC, CAMDEN ASSET MANAGEMENT L P /CA, Balyasny Asset Management L.P., Alberta Investment Management Corp, DLD Asset Management, LP, Point72 Asset Management, L.P., Davidson Kempner Capital Management LP, and JPMORGAN CHASE & CO.
This page lists
63
institutional bondholders reporting positions
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.